Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价XZ120在恶性肿瘤患者中的安全性、耐受性、药代动力学特征及初步有效性的Ⅰ期临床研究
[Translation] Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of XZ120 in patients with malignant tumors
评价XZ120治疗恶性肿瘤患者的安全性、耐受性、药代动力学特征及初步有效性。
[Translation] To evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of XZ120 in the treatment of patients with malignant tumors.
SPH4336联合内分泌治疗伴脑转移的HR阳性、HER2阴性转移性乳腺癌的Ⅱ期临床研究
[Translation] Phase II clinical study of SPH4336 combined with endocrine therapy for HR-positive, HER2-negative metastatic breast cancer with brain metastases
评价SPH4336联合内分泌治疗伴脑转移的HR阳性、HER2阴性转移性乳腺癌患者的安全性和有效性。
[Translation] To evaluate the safety and efficacy of SPH4336 combined with endocrine therapy in patients with HR-positive, HER2-negative metastatic breast cancer with brain metastases.
SPH4336联合内分泌治疗既往经CDK4/6抑制剂联合内分泌治疗进展的HR阳性、HER2阴性局部晚期或转移性乳腺癌的II/III期临床研究
[Translation] A phase II/III clinical study of SPH4336 combined with endocrine therapy for HR-positive, HER2-negative locally advanced or metastatic breast cancer that has progressed on CDK4/6 inhibitor combined with endocrine therapy
评价SPH4336联合内分泌治疗经CDK4/6抑制剂联合内分泌治疗进展的HR阳性、HER2阴性局部晚期或转移性乳腺癌患者的安全性和有效性。
[Translation] To evaluate the safety and efficacy of SPH4336 combined with endocrine therapy in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer who have progressed on CDK4/6 inhibitor combined with endocrine therapy.
100 Clinical Results associated with Shanghai Pharmaceutical Group (Benxi) North Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Shanghai Pharmaceutical Group (Benxi) North Pharmaceutical Co., Ltd.
100 Deals associated with Shanghai Pharmaceutical Group (Benxi) North Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Shanghai Pharmaceutical Group (Benxi) North Pharmaceutical Co., Ltd.